Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
'This acquisition exemplifies Sun Pharma's commitment to supporting patients and growing its innovative therapies business,' said Dilip Shanghvi, Chairman & Managing Director of Sun Pharma. 'By adding UNLOXCYT™, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio.'
Financial Terms
Sun Pharma has acquired all outstanding shares of Checkpoint at a price of $4.10 per share in cash, without interest, plus one non-tradable contingent value right (CVR) per share representing the right to receive up to an additional $0.70 in cash, without interest, if certain specified milestones are met, as set out in the terms and conditions of the contingent value rights agreement.
About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)
Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).
About Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma ('cSCC') is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. Important risk factors for cSCC include chronic ultraviolet exposure and immunosuppressive conditions. While most cases are localized tumors amenable to curative resection, each year approximately 40,000 cases become advanced and an estimated 15,000 people in the United States die from this disease. In addition to being a life-threatening disease, cSCC causes significant functional morbidities and cosmetic deformities due to tumors that commonly arise in the head and neck region, and that invade blood vessels, nerves and vital organs, such as the eye or ear.
UNLOXCYT™ INDICATION and IMPORANT SAFETY INFORMATION
INDICATION
UNLOXCYT™ (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
IMPORTANT SAFETY INFORMATION
Severe and Fatal Immune-Mediated Adverse Reactions
Immune-Mediated Pneumonitis
Immune-Mediated Colitis
Immune-Mediated Hepatitis
Immune-Mediated Endocrinopathies
Adrenal Insufficiency
Hypophysitis
Thyroid Disorders
Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis
Immune-Mediated Nephritis with Renal Dysfunction
Immune-Mediated Dermatologic Adverse Reactions
Other Immune-Mediated Adverse Reactions
Infusion-Related Reactions
Complications of Allogeneic HSCT
Embryo-Fetal Toxicity
Common Adverse Reactions
The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection.
Please see full Prescribing Information.
Sun Pharma Contacts:
Investors
Dr. Abhishek Sharma
+91 22 4324 2929
[email protected]
Media (Global)
Gaurav Chugh
+91 22 4324 5373
[email protected]
Media (USA)
James Freeman
+1 978-808-6956
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/sun-pharma-completes-its-acquisition-of-checkpoint-therapeutics-302469542.html
SOURCE Sun Pharma
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Forbes
23 minutes ago
- Forbes
A Linchpin Of American Higher Education Funding Is At Risk
-And 2026 Could Be Worse While headlines scream about a potential 40% collapse in new international student enrollment for Fall 2025 – translating to a 15% overall drop, 150,000 fewer students, $7 billion in lost revenue, and 60,000 vanished jobs according to a recent report by NAFSA, The Association of International Educators, American universities face a far more insidious long-term threat. The true crisis isn't just the immediate shock to the Class of 2029; it's the accelerating exodus of talent, particularly from China and India, towards competitor nations in 2026-2027 and beyond. The pipeline sustaining a critical revenue stream and global academic standing is springing leaks that may prove impossible to plug. The Immediate Crunch: Visa Chaos and Plummeting Interest The mechanisms driving the 2025 decline are stark: The economic impact is geographically widespread but deeply concentrated: California faces a potential $1 billion hit, New York $988 million, Massachusetts $619 million, Texas $388 million, and Florida $243 million. Beyond 2025: The Looming Structural Shift The greater peril lies beyond the immediate enrollment cliff. The combination of persistent visa hurdles, perceived hostility, and aggressive recruitment by competitor nations is fundamentally altering the aspirations of the next cohort of international students, especially from the two largest sending countries: China and India. Vulnerable Institutions: Not Just the Obvious Suspects While elite, well-endowed universities will feel the pain (Columbia, NYU, Northeastern, USC, CMU, and Illinois CU all have high international undergrad populations), they possess larger buffers. The existential threat is to a different tier. A Brookings study found that these colleges are most at risk: The Bleeding Has Already Started This isn't theoretical: The Unsustainable Model Exposed International students contributed over $44 billion to the U.S. economy in 2023-24 – more than Disney's global revenue. They are not merely students; they are full-fee-paying customers subsidizing the education of domestic students and university operations. At private institutions, where discount rates for domestic students often exceed 50%, international full-pay students are the linchpin keeping the financial model afloat. Public universities rely on their premium tuition to offset stagnant state funding. A Call Beyond Expedited Visas While NAFSA rightly calls for expedited F-1/M-1/J-1 processing and exemptions from travel bans for students (with security checks intact), this addresses only the immediate 2025 logjam. The deeper challenge requires a fundamental shift: The $7 billion crisis of 2025 is severe. But the silent hemorrhage of future talent pipelines threatens to inflict a slow, debilitating wound on American higher education's finances, global competitiveness, and intellectual vitality. If the students from Beijing, Hyderabad, Lagos, and São Paulo stop dreaming of American degrees by 2026, the foundations of the system itself begin to crumble. The linchpin isn't just at risk; it's being actively pried loose.
Yahoo
an hour ago
- Yahoo
Canada's Gildan to acquire US apparel brand HanesBrands for $4.4bn
Canadian apparel manufacturer Gildan Activewear has signed a definitive merger agreement to acquire US apparel brandHanesBrands for an enterprise value of $4.4bn. The transaction will combine the strengths of both companies to create what is described as a 'global basic apparel leader'. The merger will expand Gildan's scale and strengthen its market positioning, combining its activewear leadership with HanesBrands' innerwear retail expertise. Gildan president and CEO Glenn Chamandy stated: 'With this transaction, our revenues will double and we achieve a scale that distinctly sets us apart. The combination with HanesBrands strengthens our positioning with an opportunity to expand the heritage Hanes brand presence in activewear across channels, while enhancing Gildan's retail reach for its portfolio of brands.' Gildan's headquarters will remain in Montréal, Québec, with a combined presence in Winston-Salem, North Carolina. HanesBrands shareholders will receive 0.102 common shares of Gildan and $0.80 in cash for each share of HanesBrands stock, owning 19.9% of Gildan shares post-transaction. The transaction, subject to shareholder and regulatory approvals, is expected to close between late 2025 and early 2026. The combined company will benefit from enhanced product diversification, an advanced low-cost manufacturing network and significant synergy opportunities, with at least $200m in annual cost synergies expected by 2028. Gildan has obtained $2.3bn of committed financing for the acquisition and anticipates a net debt leverage ratio of 2.6 times adjusted earnings before interest, taxes, depreciation and amortisation at closing. Gildan has reaffirmed its full-year 2025 revenue and earnings per share guidance and provided a three-year outlook for 2026 to 2028, anticipating 3% to 5% net sales growth, 3% to 4% capital expenditures annually to support growth and vertical integration, and enhanced shareholder returns. HanesBrands board of directors chairman Bill Simon stated: 'As part of Gildan, HanesBrands will benefit from an even stronger financial and operational foundation that will provide new growth opportunities – helping to power further innovation, a broader product offering and greater reach across channels and geographies. We are confident that this transaction and the next chapter with Gildan is the right next step for HanesBrands and will honour and build on its long history for the benefit of all our stakeholders.' Morgan Stanley & Co and CIBC Capital Markets acted as financial advisors to Gildan while Sullivan & Cromwell and Stikeman Elliott as legal advisors. Goldman Sachs & Co and Evercore served as lead financial advisors to Hanesbrands, and Jones Day and Blake, Cassels & Graydon were legal advisors. "Canada's Gildan to acquire US apparel brand HanesBrands for $4.4bn" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
